# reload+after+2024-01-21 00:46:27.708614
address1§4400 Biscayne Boulevard
city§Miami
state§FL
zip§33137
country§United States
phone§305 575 4100
website§https://www.opko.com
industry§Diagnostics & Research
sector§Healthcare
longBusinessSummary§OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
fullTimeEmployees§4196
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Phillip  Frost Ph.D.', 'age': 87, 'title': 'Chairman & CEO', 'yearBorn': 1936, 'fiscalYear': 2022, 'totalPay': 972200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jane H. Hsiao M.B.A., Ph.D.', 'age': 76, 'title': 'Vice Chairman & Chief Technical Officer', 'yearBorn': 1947, 'fiscalYear': 2022, 'totalPay': 912200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Elias Adam Zerhouni M.D.', 'age': 72, 'title': 'President & Vice Chairman', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 1412600, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Adam E. Logal', 'age': 45, 'title': 'Senior VP, CFO, Chief Accounting Officer & Treasurer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 712200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven D. Rubin Esq., J.D.', 'age': 63, 'title': 'Executive VP of Administration & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 822200, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Akhtar  Ashfaq', 'title': 'Senior Vice President of Clinical Research & Development and Medical Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jane Pine Wood Esq., J.D.', 'age': 61, 'title': 'Chief Legal Officer of Bio-Reference Laboratories', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gary J. Nabel M.D., Ph.D.', 'age': 69, 'title': 'Chief Innovation Officer & Director', 'yearBorn': 1954, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David  Okrongly Ph.D.', 'age': 64, 'title': 'President of OPKO Diagnostics', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Charles W. Bishop', 'age': 71, 'title': 'Chief Executive Officer of OPKO Renal', 'yearBorn': 1952, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§10
compensationRisk§7
shareHolderRightsRisk§3
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.829
priceToSalesTrailing12Months§0.7923797
currency§USD
dateShortInterest§1702598400
forwardEps§-0.18
pegRatio§-0.3
exchange§NMS
quoteType§EQUITY
shortName§Opko Health, Inc.
longName§OPKO Health, Inc.
firstTradeDateEpochUtc§815322600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§d21495bc-3f90-3f7e-ab0d-a17a57b35371
gmtOffSetMilliseconds§-18000000
targetHighPrice§8.5
targetLowPrice§2.0
targetMeanPrice§4.42
targetMedianPrice§4.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§6
quickRatio§1.322
grossMargins§0.27648002
ebitdaMargins§-0.04881
trailingPegRatio§None
